Mortality from pulmonary injury and Gamma variant of COVID19 | VHRM – Dove Medical Press

by | Nov 2, 2022 | COVID-19

Introduction
The SARS-CoV-2 disease predisposes infected individuals to thrombosis, the underlying mechanisms of which are not fully understood. The balance between pro-coagulant factors and natural coagulation inhibitors in critically ill patients with Covid-19 is fundamental to the prevention and treatment of complications.1 A study confirms that critically ill patients with coronavirus may develop arterial and deep vein thrombosis, which increased the risk of mortality. Thus, adequate early conduct can improve the overall survival rate, especially among patients 60 years of age or younger.2
D dimer concentrations are high in nearly all patients with Covid-19. Moreover, concentrations ≥3000 ng/mL (more than 13-fold higher than the normal range) seem to be reliable with regard to screening for deep vein thrombosis (DVT) in the lower limbs.3
Anticoagulant therapy is associated with a reduction in mortality. However, the best dose and option timing remain the object of study. One study found a 2.5% rate of major hemorrhagic events in a group given an intermediate dose, with a 1.07% rate of fatal events, compared to only four major hemorrhagic events (1.4%) and no mortality in the group given a standard prophylactic dose.4
The sequencing of the genome of the virus sampled in the city of Manaus (Brazil) between November 2020 and January 2021 revealed the emergence and circulation of a worrisome novel variant of SARS-CoV-2. The Gamma variant line acquired 17 mutations, including three in the spike protein (K417T, E484K and N501Y), a …

Article Attribution | Read More at Article Source

Share This